 Celldex Therapeutics, Inc. NASDAQ:CLDX Equities researchers at Cantor Fitzgerald lifted their FY2020 earnings per share estimates for shares of Celldex Therapeutics in a report issued on Wednesday, July 1st. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn 1.76 per share for the year, up from their prior estimate of ... 